• Envoy Medical disclosed initial interim results from its pivotal US study of investigational, fully implanted Acclaim cochlear implant, with findings already presented at recent audiology and otolaryngology conferences.
• Early data from first 10 patients at 6 months showed no serious safety issues, with hearing performance improving versus pre-implant levels.
• Participants reported near-continuous daily use, supporting Envoy’s strategy to target patients who avoided traditional cochlear implants due to reliance on external processors.
• Quality-of-life measures improved, with tinnitus symptoms easing in patients who reported tinnitus before surgery.
• Additional clinical presentations are scheduled for May 8, 2026 and May 11, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.